Mathew J. Garnett

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations	2024	Azadeh C. Bashi Elizabeth A. Coker Krishna C. Bulusu Patricia Jaaks Claire Crafter Howard Lightfoot Marta Milo Katrina McCarten David F. Jenkins Dieudonne van der Meer
+	Figure S4 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S10 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S9 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S6 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S11 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S1 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S5 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S8 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S3 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S7 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S2 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S7 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S9 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S3 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S10 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S6 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S8 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S4 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S11 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S1 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S5 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Figure S2 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia	2023	Srividya B. Balachander Steven W. Criscione Kate F. Byth Justin Cidado Ammar Adam Paula Lewis Terry Macintyre Shenghua Wen Deborah Lawson Kathleen A. Burke
+	Author response: A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates	2020	Dennis Wang James Hensman Ginte Kutkaite Tzen S. Toh Ana Galhoz Howard Lightfoot Wanjuan Yang Maryam Soleimani Syd Barthorpe Tatiana Mironenko
+ PDF Chat	Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies	2018	Federica Eduati Patricia Jaaks Christoph A. Merten Mathew J. Garnett Julio Sáez-Rodríguez
+ PDF Chat	Cell Model Passports—a hub for clinical, genetic and functional datasets of preclinical cancer models	2018	Dieudonne van der Meer Syd Barthorpe Wanjuan Yang Howard Lightfoot Caitlin Hall James Gilbert Hayley E. Francies Mathew J. Garnett
+	Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type–Specific Dynamic Logic Models	2017	Federica Eduati Victoria Doldàn-Martelli Bertram Klinger Thomas Cokelaer Anja Sieber Fiona Kogera Mathurin Dorel Mathew J. Garnett Nils Blüthgen Julio Sáez-Rodríguez
+ PDF Chat	Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy	2016	Theo Knijnenburg Gunnar W. Klau Francesco Iorio Mathew J. Garnett Ultan McDermott Ilya Shmulevich Lodewyk F.A. Wessels
+	Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy	2016	Theo Knijnenburg Gunnar W. Klau Francesco Iorio Mathew J. Garnett Ultan McDermott Ilya Shmulevich Lodewyk F.A. Wessels
+ PDF Chat	Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties	2013	Michael P. Menden Francesco Iorio Mathew J. Garnett Ultan McDermott Cyril H. Benes Pedro J. Ballester Julio Sáez-Rodríguez

Common Coauthors

Coauthor	Papers Together
Patricia Jaaks	24
Omid Tavana	23
Elizabeth A. Coker	23
Stephen E. Fawell	23
Justin Cidado	23
Francis D. Gibbons	22
Thomas W. Gero	22
Ammar Adam	22
Jeffrey Varnes	22
William McCoull	22
Kathleen A. Burke	22
Stephanos Ioannidis	22
Andrea Newbold	22
Areya Tabatabai	22
Paula Lewis	22
Srividya B. Balachander	22
Michael Zinda	22
J. Paul Secrist	22
Kate F. Byth	22
Deborah Lawson	22
Ricky W. Johnstone	22
Barry R. Davies	22
Gareth P. Gregory	22
Jamal Saeh	22
Terry Macintyre	22
Jeffrey W. Tyner	22
Martin Wild	22
Steven W. Criscione	22
Nancy Su	22
R. Bruce Diebold	22
Shannon K. McWeeney	22
Alwin G. Schuller	22
Edward J. Hennessy	22
Shenghua Wen	22
Tristan Lubinski	22
Stephen E. Kurtz	22
Eric T. Gangl	22
Julio Sáez-Rodríguez	4
Ultan McDermott	4
Francesco Iorio	3
Syd Barthorpe	3
Howard Lightfoot	3
Wanjuan Yang	3
Caitlin Hall	2
Tatiana Mironenko	2
Michael P. Menden	2
Laura Richardson	2
Dieudonne van der Meer	2
Federica Eduati	2
Lodewyk F.A. Wessels	2

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	MEIGO: an open-source software suite based on metaheuristics for global optimization in systems biology and bioinformatics	2014	José A. Egea David Henriques Thomas Cokelaer Alejandro F. Villaverde Aidan MacNamara Diana-Patricia Danciu Julio R. Banga Julio Sáez-Rodríguez	2
+ PDF Chat	Markov Logic Networks in the Analysis of Genetic Data	2010	Nikita A. Sakhanenko David J. Galas	2
+ PDF Chat	Integrative Modelling of the Influence of MAPK Network on Cancer Cell Fate Decision	2013	Luca Grieco Laurence Calzone Isabelle Bernard‐Pierrot François Radvanyi Brigitte Kahn‐Perlès Denis Thieffry	1
+	Drug repositioning: identifying and developing new uses for existing drugs	2004	Ted T. Ashburn Karl B. Thor	1
+	Applied Multivariate Statistics for the Social Sciences	2012	James P. Stevens	1
+	The influence of variables on Boolean functions	1988	J. Kahn Gil Kalai Nathan Linial	1
+ PDF Chat	Fewer permutations, more accurate <i>P</i>-values	2009	Theo Knijnenburg Lodewyk F.A. Wessels Marcel J. T. Reinders Ilya Shmulevich	1
+ PDF Chat	Multilevel models improve precision and speed of IC<sub>50</sub> estimates	2016	Daniël J. Vis Lorenzo Bombardelli Howard Lightfoot Francesco Iorio Mathew J. Garnett Lodewyk F.A. Wessels	1
+	Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type–Specific Dynamic Logic Models	2017	Federica Eduati Victoria Doldàn-Martelli Bertram Klinger Thomas Cokelaer Anja Sieber Fiona Kogera Mathurin Dorel Mathew J. Garnett Nils Blüthgen Julio Sáez-Rodríguez	1
+	Functional precision cancer medicine—moving beyond pure genomics	2017	Anthony Letai	1
+	Impact of a five-dimensional framework on R&D productivity at AstraZeneca	2018	Paul Morgan Dean G. Brown Simon Lennard Mark J. Anderton J. Carl Barrett Ulf G. Eriksson Mark Fidock Bengt Hamrén Anthony Johnson Ruth March	1
+ PDF Chat	Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy	2018	Eunjung Kim Jae‐Young Kim Matthew A. Smith Eric B. Haura Alexander R.A. Anderson	1
+	Discrete dynamic network modeling of oncogenic signaling: Mechanistic insights for personalized treatment of cancer	2018	Jorge Gómez Tejeda Zañudo Steven N. Steinway Réka Albert	1
+ PDF Chat	Cell Model Passports—a hub for clinical, genetic and functional datasets of preclinical cancer models	2018	Dieudonne van der Meer Syd Barthorpe Wanjuan Yang Howard Lightfoot Caitlin Hall James Gilbert Hayley E. Francies Mathew J. Garnett	1
+	Prediction of drug combination effects with a minimal set of experiments	2019	Aleksandr Ianevski Anil K. Giri Prson Gautam Alexander Kononov Swapnil Potdar Jani Saarela Krister Wennerberg Tero Aittokallio	1
+ PDF Chat	CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer	2015	Mark D.M. Leiserson Hsin-Ta Wu Fabio Vandin Benjamin J. Raphael	1
+ PDF Chat	Independent Drug Action in Combination Therapy: Implications for Precision Oncology	2022	Deborah Plana Adam C. Palmer Peter K. Sorger	1
+ PDF Chat	Angiogenic Activity of Breast Cancer Patients’ Monocytes Reverted by Combined Use of Systems Modeling and Experimental Approaches	2015	Nicolas Guex Isaac Crespo Sylvian Bron Assia Ifticene‐Treboux Eveline Faes-van’t Hull Solange Kharoubi Robin Liechti Patricia Werffeli Mark Ibberson F. Majo	1